What one share of Acrivon Therapeutics holds
We are a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing our proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform designed to quantify compound-specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights.
Acrivon Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.88 |
|---|---|
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$1.63 |
| Cash and investments | $0.97 |
| Book value | $2.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$9.32 | $0.14 | −$8.16 | — | −$13.45 |
| 2022 | — | −$7.56 | $0.53 | −$7.83 | — | — |
| 2023 | — | −$2.74 | $0.06 | −$1.99 | — | $5.38 |
| 2024 | — | −$2.38 | $0.08 | −$2.03 | — | $5.66 |
| 2025 | — | −$2.02 | $0.04 | −$1.70 | — | $3.56 |
Common questions about Acrivon Therapeutics
How much does one share of Acrivon Therapeutics earn?
Over the last 12 months, Acrivon Therapeutics lost $1.88 for each share.
Does Acrivon Therapeutics pay a dividend?
Acrivon Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Acrivon Therapeutics’s book value per share?
Acrivon Therapeutics’s book value is $2.02 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Acrivon Therapeutics have?
Each share of Acrivon Therapeutics has $0.97 of cash and investments, as of June 30, 2026.
What is Acrivon Therapeutics’s free cash flow per share?
−$1.63 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Acrivon Therapeutics bought back shares?
Acrivon Therapeutics’s share count rose about 2109% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.